Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Reneuron Group Plc. (RNUGF)

Reneuron Group Plc. (RNUGF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 63
  • Shares Outstanding, K 57,174
  • Annual Sales, $ 640 K
  • Annual Income, $ -6,520 K
  • 60-Month Beta 0.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.02
Trade RNUGF with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 07/03/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0011 +4,500.00%
on 04/10/24
0.0506 unch
on 04/26/24
+0.0081 (+19.06%)
since 02/26/24
3-Month
0.0011 +4,500.00%
on 04/10/24
0.0506 unch
on 04/26/24
-0.0009 (-1.75%)
since 12/07/23

Most Recent Stories

More News
ReNeuron Group (RENE): Extension Trial to Produce Data in Q122

LONDON, UK / ACCESSWIRE / October 11, 2021 / ReNeuron has announced that the nine-patient Phase IIa (2m cell dose) extension study (halted in June after a presumed eye infection case) has fully restarted...

RNUGF : 0.0506 (+4,500.00%)
RENE.LN : 3.375 (-2.17%)

Business Summary

ReNeuron Group plc is involved in the development of cell-based therapies. Its therapeutic candidate is CTX stem cell therapy for the treatment of patients left disabled by the effects of a stroke which are in clinical development phase. ReNeuron Group plc is headquartered in Pencoed, the United Kingdom....

See More

Key Turning Points

3rd Resistance Point 0.0506
2nd Resistance Point 0.0506
1st Resistance Point 0.0506
Last Price 0.0506
1st Support Level 0.0506
2nd Support Level 0.0506
3rd Support Level 0.0506

See More

52-Week High 0.0515
Last Price 0.0506
Fibonacci 61.8% 0.0322
Fibonacci 50% 0.0263
Fibonacci 38.2% 0.0204
52-Week Low 0.0011

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar